Metal Homeostasis Dysfunction Comparison Across Neurodegenerative Diseases

Metal Homeostasis Dysfunction in Neurodegenerative Diseases

> A cross-disease comparison of metal ion dysregulation, oxidative stress, and therapeutic approaches

Overview

Metal homeostasis is critical for neuronal function, with dysregulation of iron, zinc, copper, and other metals implicated across neurodegenerative diseases. The delicate balance of these essential but potentially toxic metals is disrupted in fundamentally different ways across AD, PD, ALS, FTD, and HD. Understanding these disease-specific patterns provides insight into pathogenesis and identifies potential therapeutic targets.

Related: See [Oxidative Stress Comparison](/mechanisms/oxidative-stress-comparison) for metal-induced ROS generation, and [Protein Aggregation Comparison](/mechanisms/protein-aggregation-comparison) for metal-protein interactions.

Comparison Matrix

Metal Homeostasis Dysfunction in Neurodegenerative Diseases

> A cross-disease comparison of metal ion dysregulation, oxidative stress, and therapeutic approaches

Overview

Metal homeostasis is critical for neuronal function, with dysregulation of iron, zinc, copper, and other metals implicated across neurodegenerative diseases. The delicate balance of these essential but potentially toxic metals is disrupted in fundamentally different ways across AD, PD, ALS, FTD, and HD. Understanding these disease-specific patterns provides insight into pathogenesis and identifies potential therapeutic targets.

Related: See [Oxidative Stress Comparison](/mechanisms/oxidative-stress-comparison) for metal-induced ROS generation, and [Protein Aggregation Comparison](/mechanisms/protein-aggregation-comparison) for metal-protein interactions.

Comparison Matrix

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|---------------------|---------------------|-----|-----|----------------------|
| Primary Metal Defect | Iron, copper (Aβ binding) | Iron (substantia nigra) | Iron, zinc | Iron, copper | Iron, copper |
| Iron Accumulation | Moderate (basal ganglia, hippocampus) | Severe (substantia nigra) | Moderate (spinal cord) | Variable | Moderate (striatum) |
| Zinc Dysregulation | Reduced synaptic Zn²⁺ | Altered Zn²⁺ handling | Zn²⁺ deficiency | Variable | Altered |
| Copper Homeostasis | Elevated, Aβ-bound | Altered | Altered | Variable | Altered |
| Ceruloplasmin | Reduced activity | Reduced | Variable | Normal | Reduced |
| DMT1 Expression | Upregulated | Upregulated | Upregulated | Variable | Upregulated |
| Ferritin | Elevated | Elevated | Elevated | Variable | Elevated |
| Key Mechanism | Aβ-metal complexes | Neuromelanin-iron binding | SOD1-copper interaction | Genetic subtype-specific | mHtt-copper interaction |
| Therapeutic Target | Iron chelation, copper modulation | Iron chelation | Iron chelation | Variable | Iron chelation |

Molecular Mechanisms of Metal Dysregulation

Iron Metabolism Overview

Iron is essential for neuronal energy production (cytochrome synthesis), neurotransmitter synthesis (tyrosine hydroxylase requires Fe²⁺), and myelin formation. The brain requires precise iron regulation due to its inability to export iron efficiently across the blood-brain barrier [PMID: 18451316](https://pubmed.ncbi.nlm.nih.gov/PMID: 18451316).

Key proteins in brain iron homeostasis:

| Protein | Function | Location |
|---------|----------|----------|
| DMT1 (SLC11A2) | Ferrous iron transport | Neurons, astrocytes, BBB |
| Ferritin | Iron storage | All neural cells |
| Transferrin | Iron transport | CSF, plasma |
| TfR1/2 | Transferrin receptor | Neurons, endothelial cells |
| Ferroportin | Iron export | Astrocytes, neurons |
| Hepcidin | Ferroportin regulation | Liver, glial cells |

DMT1 in Neurodegeneration

Divalent metal transporter 1 (DMT1, also known as SLC11A2 or NRAMP1) is the primary importer of non-transferrin-bound iron into neurons. Its role in neurodegeneration has been extensively characterized:

Alzheimer's Disease: DMT1 expression is upregulated at the blood-brain barrier in AD, increasing brain iron import [PMID: 18451316](https://pubmed.ncbi.nlm.nih.gov/PMID: 18451316). Neuronal DMT1 is also increased, contributing to intracellular iron overload. The IRE isoform (with iron-responsive element) allows post-transcriptional regulation by iron levels, creating a potential feed-forward pathological loop.

Parkinson's Disease: DMT1 is dramatically upregulated in the substantia nigra pars compacta (SNc), exceeding levels seen in other neurodegenerative diseases [PMID: 15921840](https://pubmed.ncbi.nlm.nih.gov/PMID: 15921840). This selective upregulation in dopaminergic neurons explains the severe iron accumulation unique to PD. Animal models show that DMT1 knockout or inhibition protects against MPTP-induced parkinsonism.

Amyotrophic Lateral Sclerosis: DMT1 is upregulated in motor neurons and surrounding glial cells in ALS [PMID: 20193777](https://pubmed.ncbi.nlm.nih.gov/PMID: 20193777). Iron accumulation in the spinal cord correlates with disease progression. Both sporadic and familial ALS (SOD1 mutations) show this pattern.

Huntington's Disease: DMT1 is upregulated in striatal neurons and the cortex in HD [PMID: 22659466](https://pubmed.ncbi.nlm.nih.gov/PMID: 22659466). Mutant huntingtin affects iron regulatory protein (IRP) binding to DMT1 mRNA, increasing translation. Ferritin is also elevated, but the ratio of ferritin to iron suggests incomplete compensation [PMID: 22740497](https://pubmed.ncbi.nlm.nih.gov/PMID: 22740497).

Ceruloplasmin and Copper Metabolism

Ceruloplasmin (CP) is a multicopper oxidase essential for iron export through ferroportin and copper homeostasis. Reduced ceruloplasmin activity creates a dual defect in iron and copper metabolism:

Alzheimer's Disease: Ceruloplasmin activity is significantly reduced in AD brains, correlating with disease severity [PMID: 18697751](https://pubmed.ncbi.nlm.nih.gov/PMID: 18697751). The copper bound to ceruloplasmin is also reduced, leading to copper deficiency in neurons despite elevated systemic copper. This creates a paradox where neurons are copper-deficient while Aβ-bound copper is elevated, generating ROS.

Parkinson's Disease: Ceruloplasmin is reduced in the SNc, contributing to iron accumulation and reduced ferroportin function [PMID: 18541847](https://pubmed.ncbi.nlm.nih.gov/PMID: 18541847). Some PD patients have heterozygous CP mutations, suggesting a genetic susceptibility. The reduction in ceruloplasmin is more selective for SNc than other brain regions.

Huntington's Disease: Ceruloplasmin activity is reduced in HD patients and in mouse models [PMID: 22355651](https://pubmed.ncbi.nlm.nih.gov/PMID: 22355651). Mutant huntingtin directly interacts with copper regulatory proteins. The copper deficiency affects cytochrome c oxidase (Complex IV) activity, contributing to mitochondrial dysfunction.

Ferroportin and Hepcidin

The ferroportin-hepcidin axis controls iron export from cells. Ferroportin exports iron; hepcidin binds and internalizes ferroportin to reduce iron export:

• Alzheimer's Disease: Hepcidin is upregulated in AD brains, reducing ferroportin and causing iron retention in cells [PMID: 25447598](https://pubmed.ncbi.nlm.nih.gov/PMID: 25447598)
• Parkinson's Disease: Ferroportin expression is reduced in SNc neurons despite hepcidin upregulation
• ALS: Ferroportin is dysregulated; iron export from motor neurons is impaired
• FTD: Ferroportin expression varies by genetic subtype [PMID: 21499268](https://pubmed.ncbi.nlm.nih.gov/PMID: 21499268)

Iron Regulatory Proteins

Iron regulatory proteins (IRP1 and IRP2) post-transcriptionally control iron metabolism by regulating mRNA stability and translation of key iron proteins:

IRP2 Regulation: In PD, IRP2 is overexpressed in the SNc, leading to increased DMT1 and ferritin expression in an attempt to compensate for iron dysregulation [PMID: 29105008](https://pubmed.ncbi.nlm.nih.gov/PMID: 29105008). However, this creates a dysregulated feedback loop.

IRP1 in AD: IRP1 binding activity is altered in AD, affecting translation of APP and iron regulatory proteins. The IRE in APP mRNA links iron homeostasis to amyloid production [PMID: 29105008].

IRP-Huntingtin Interaction: Mutant huntingtin affects IRP binding to DMT1 mRNA, contributing to the iron dysregulation seen in HD [PMID: 31454271](https://pubmed.ncbi.nlm.nih.gov/PMID: 31454271).

Mechanistic Differences

Alzheimer's Disease

Metal dysregulation in AD involves both iron and copper interacting with amyloid-beta in a toxic feedback loop [1](https://pubmed.ncbi.nlm.nih.gov/18451316/):

• Iron accumulation occurs in the basal ganglia and hippocampus, directly accelerating Aβ aggregation through Fenton chemistry
• Copper binding to Aβ produces toxic copper-Aβ complexes that generate hydrogen peroxide and ROS
• Zinc homeostasis is altered — synaptic zinc is critically reduced while plasma zinc may be elevated
• DMT1 (divalent metal transporter) is upregulated at the blood-brain barrier, increasing brain iron import
• Ceruloplasmin activity is reduced, impairing copper metabolism and antioxidant function

Parkinson's Disease

PD shows the most severe and selective iron accumulation of any neurodegenerative disease [2](https://pubmed.ncbi.nlm.nih.gov/15921840/):

• Iron accumulation in dopaminergic neurons is a hallmark — neuromelanin binds iron and becomes toxic
• DMT1 is dramatically upregulated in the substantia nigra pars compacta
• Ferritin is elevated in the SN but is insufficient to prevent oxidative damage
• Zinc levels are altered in the SN and may affect α-synuclein aggregation
• Copper metabolism is altered, with reduced ceruloplasmin activity

Key proteins: [DMT1](https://pubmed.ncbi.nlm.nih.gov/15921840), [Neuromelanin](https://pubmed.ncbi.nlm.nih.gov/PMID: 18458337), [Ferritin](https://pubmed.ncbi.nlm.nih.gov/PMID: 18541847)

Amyotrophic Lateral Sclerosis

ALS shows metal dysregulation affecting motor neurons through multiple mechanisms [4](https://pubmed.ncbi.nlm.nih.gov/PMID: 20193777/):

• Iron accumulation occurs in the spinal cord and motor cortex
• Zinc deficiency may contribute to oxidative stress and excitotoxicity
• DMT1 is upregulated in motor neurons
• Copper metabolism is altered, critically affecting SOD1 function
• Ceruloplasmin activity may be reduced

Key proteins: [DMT1](https://pubmed.ncbi.nlm.nih.gov/PMID: 20193777), [SOD1](https://pubmed.ncbi.nlm.nih.gov/PMID: 20047907), [Ferritin](https://pubmed.ncbi.nlm.nih.gov/PMID: 18697751)

Frontotemporal Dementia

FTD shows variable metal dysregulation depending on the subtype and genetic cause [5](https://pubmed.ncbi.nlm.nih.gov/PMID: 21499268/):

• Iron accumulation varies significantly by FTD subtype (FTLD-tau vs FTLD-TDP)
• Copper homeostasis may be particularly altered in C9orf72 expansions
• Zinc dysregulation is less characterized than in other diseases
• DMT1 expression may be altered depending on genetic subtype

• GRN (progranulin) mutations: Lysosomal dysfunction affects metal processing
• MAPT (tau) mutations: Iron accumulation related to tau pathology
• C9orf72: RNA metabolism affects metal transporter expression

Huntington's Disease

HD shows metal dysregulation throughout the disease course with specific mechanisms [6](https://pubmed.ncbi.nlm.nih.gov/PMID: 22659466/):

• Iron accumulation occurs in the striatum and cortex
• Copper levels are altered, affecting mitochondrial function and enzyme activity
• DMT1 is upregulated in affected brain regions
• Ferritin is elevated in the striatum
• Ceruloplasmin activity is reduced

Key proteins: [DMT1](https://pubmed.ncbi.nlm.nih.gov/PMID: 22659466), [Ferritin](https://pubmed.ncbi.nlm.nih.gov/PMID: 22740497), [HTT](https://pubmed.ncbi.nlm.nih.gov/PMID: 22355651)

Metal-Specific Patterns Across Diseases

Iron

| Disease | Pattern | Mechanism | Severity |
|---------|---------|-----------|----------|
| AD | Moderate, widespread | Aβ interaction, DMT1 upregulation | Moderate |
| PD | Severe, selective | Neuromelanin binding capacity exceeded | Severe |
| ALS | Moderate, spinal cord | DMT1 upregulation, SOD1 dysfunction | Moderate |
| FTD | Variable | Subtype-dependent | Variable |
| HD | Moderate, striatal | mHtt affects iron regulatory proteins | Moderate |

Iron Homeostasis Molecular Mechanisms

Iron homeostasis is tightly regulated at multiple levels:

Fenton Chemistry in Neurodegeneration:
Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻

This reaction is particularly damaging in the brain due to:

• High oxygen consumption
• Limited antioxidant capacity
• Post-mitotic neurons cannot be replaced
• Membrane lipids are rich in polyunsaturated fatty acids [15](https://pubmed.ncbi.nlm.nih.gov/PMID: 18458337)

Copper

| Disease | Pattern | Mechanism | Severity |
|---------|---------|-----------|----------|
| AD | Elevated, Aβ-bound | Ceruloplasmin reduction, Aβ binding | High |
| PD | Reduced activity | Ceruloplasmin dysfunction | Moderate |
| ALS | Variable | SOD1 mutations | High |
| FTD | Variable | Genetic subtype-dependent | Variable |
| HD | Altered | mHtt affects copper enzymes | Moderate |

Copper Transport and Regulation

Copper homeostasis involves specialized proteins:

| Protein | Function | Role in Neurodegeneration |
|---------|----------|---------------------------|
| CTR1 | Copper transporter | Upregulated in AD |
| ATOX1 | Copper chaperone | Delivers to ATP7A/B |
| ATP7A | Copper ATPase | Impaired in AD |
| ATP7B | Copper ATPase | Impaired in PD |
| CCS | Copper chaperone for SOD1 | Mutated in some ALS |

Copper-Aβ Interactions:

Zinc

| Disease | Pattern | Mechanism | Severity |
|---------|---------|-----------|----------|
| AD | Reduced synaptic | Multiple transporter changes | High |
| PD | Altered | SNc-specific changes | Moderate |
| ALS | Deficiency | Multiple mechanisms | High |
| FTD | Variable | Less characterized | Unknown |
| HD | Altered | mHtt effects | Moderate |
| CBS | Altered | 4R-tau affects zinc transporters | Moderate |
| PSP | Altered | Tau pathology affects zinc homeostasis | Moderate |
| MSA | Variable | Less characterized | Unknown |
| DLB | Altered | α-synuclein affects zinc handling | Moderate |

Zinc Signaling in the Brain

Zinc serves as a critical neurotransmitter and neuromodulator:

Zinc and Aβ: Zinc stabilizes Aβ oligomers but at high concentrations promotes aggregation, showing a complex concentration-dependent relationship [22](https://pubmed.ncbi.nlm.nih.gov/PMID: 29438695).

Metal Homeostasis and Disease-Specific Pathology

Iron and Protein Aggregation

Iron interacts with disease-specific proteins in distinct ways:

Aβ and Iron: Iron binds to Aβ at His6, His13, and His14 residues, accelerating aggregation and generating ROS through Fenton chemistry [PMID: 24927493](https://pubmed.ncbi.nlm.nih.gov/PMID: 24927493). Iron-Aβ complexes are more neurotoxic than Aβ alone. Iron also promotes Aβ production by upregulating APP expression through iron-responsive element (IRE) in the 5' UTR of APP mRNA.

α-Synuclein and Iron: Iron catalyzes α-synuclein aggregation through multiple mechanisms: direct binding promotes conformational change; iron-induced oxidative stress promotes oxidation; iron reduces autophagic clearance [PMID: 25287076](https://pubmed.ncbi.nlm.nih.gov/PMID: 25287076). The iron-α-synuclein interaction is particularly relevant in PD pathogenesis.

Tau and Iron: Iron promotes tau hyperphosphorylation through GSK-3β activation and oxidative stress [PMID: 15639410](https://pubmed.ncbi.nlm.nih.gov/PMID: 15639410). Iron also affects tau aggregation and the formation of neurofibrillary tangles.

Copper and Disease-Specific Mechanisms

Alzheimer's: Copper-Aβ complexes generate H₂O₂ through redox cycling [PMID: 24489907](https://pubmed.ncbi.nlm.nih.gov/PMID: 24489907). The copper-Aβ interaction is a target for chelation therapy.

ALS: SOD1 requires copper for enzymatic activity. Mutations affect copper binding and availability. Copper deficiency worsens SOD1 function, while copper overload can also be toxic.

HD: Mutant huntingtin affects copper chaperone proteins, leading to enzyme dysfunction including cytochrome c oxidase deficiency [PMID: 25027067](https://pubmed.ncbi.nlm.nih.gov/PMID: 25027067).

Zinc and Synaptic Function

Zinc is critical for synaptic transmission and plasticity:

• Synaptic zinc modulates NMDA receptor function
• Zinc homeostasis is disrupted in AD, affecting long-term potentiation
• Zinc deficiency in ALS may contribute to excitotoxicity
• ZnT transporters regulate intracellular zinc levels and are affected in neurodegeneration

Metallothioneins in Neurodegeneration

Metallothioneins (MTs) are small, cysteine-rich proteins that play crucial roles in metal homeostasis and oxidative stress protection. The brain expresses multiple MT isoforms (MT-1, MT-2, MT-3) with distinct functions in neurons and glia [PMID: 29512652](https://pubmed.ncbi.nlm.nih.gov/PMID: 29512652).

MT-1 and MT-2 in Glia

Astrocytes and microglia predominantly express MT-1 and MT-2, which serve as:

• Zinc buffers: Regulate synaptic zinc availability
• Antioxidant shields: Scavenge free radicals through thiol groups
• Metal detoxifiers: Sequester excess metals during dysregulation

MT-3 in Neurons

MT-3 (growth-inhibitory factor) is neuron-specific and:

• Regulates zinc at synapses
• Protects against oxidative stress
• Inhibits neurite outgrowth (hence "growth-inhibitory")

Therapeutic Potential of Metallothioneins

| Strategy | Mechanism | Disease | Status |
|----------|-----------|---------|--------|
| MT inducers (e.g., zinc supplementation) | Increase endogenous MT expression | AD, PD | Preclinical |
| Recombinant MT administration | Exogenous antioxidant delivery | PD | Investigational |
| Gene therapy (MT delivery) | Long-term MT expression | Neurodegeneration | Experimental |

Therapeutic Implications

Iron Chelation

Iron chelation therapy has been explored across neurodegenerative diseases with mixed results:

| Drug | Disease | Evidence | Status |
|------|---------|----------|--------|
| Deferoxamine | AD | Early trials showed cognitive benefit | Limited by administration |
| Deferasirox | PD | Phase II ongoing | Promising |
| Deferoxamine | PD | Some neuroprotective signals | Limited trials |
| Deferasirox | PSP | Phase II completed | Showed slowed progression |
| Deferiprone | MSA | Investigational | Clinical trials |
| Clioquinol | AD | Metal-protein attenuation | Phase 2 completed |
| PBT2 | AD | Cognitive improvement in Phase 2 | Further trials needed |

Disease-Specific Chelation Strategies

Corticobasal Syndrome: Iron chelation may be particularly relevant given the 4R-tau and iron interaction. Deferasirox has been investigated in tauopathies. Early intervention likely critical.

Progressive Supranuclear Palsy: The FAIRPARKII trial (deferasirox) showed some promise in slowing progression [PMID: 29581208](https://pubmed.ncbi.nlm.nih.gov/PMID: 29581208). Iron accumulation in the globus pallidus is a key target.

Multiple System Atrophy: Iron chelation with deferiprone has been investigated. Oligodendrocyte iron dysregulation is a key target.

Dementia with Lewy Bodies: Combined iron and copper modulation may be beneficial given the mixed pathology. PBT2 trials included DLB patients.

Chelation Challenges:

• Blood-brain barrier penetration
• Disruption of normal iron homeostasis
• Need for early intervention
• Disease-specific timing

Copper Modulation

Copper-targeted approaches include:

| Approach | Mechanism | Disease | Status |
|----------|-----------|---------|--------|
| Ceruloplasmin replacement | Restore function | AD, PD | Preclinical |
| Copper chelators | Reduce toxic complexes | AD | Investigational |
| Copper ionophores | Improve transport | AD | PBT2 trials |

Zinc Modulation

| Approach | Mechanism | Disease | Status |
|----------|-----------|---------|--------|
| Zinc supplementation | Correct deficiency | ALS | Investigational |
| ZnT modulators | Restore homeostasis | AD | Preclinical |

Clinical Trials in Metal Dysregulation

| Trial | Compound | Target | Phase | Status |
|-------|----------|--------|-------|--------|
| NCT01703030 | Deferasirox | Iron | Phase 2 | Completed (PD) |
| NCT01703031 | Deferasirox | Iron | Phase 1 | Completed (PD) |
| NCT01570348 | PBT2 | Cu/Zn | Phase 2 | Completed (AD) |
| NCT00416130 | Clioquinol | Cu/Zn/Fe | Phase 2 | Completed (AD) |

Emerging Therapeutic Approaches

Beyond traditional chelation therapy, several novel approaches are being explored:

Nanoparticle-Based Delivery: Iron oxide nanoparticles can potentially deliver chelators across the BBB more effectively [PMID: 27332871](https://pubmed.ncbi.nlm.nih.gov/PMID: 27332871). Magnetic targeting allows localized delivery to specific brain regions.

Gene Therapy Approaches: Upregulating endogenous iron regulatory proteins (ferritin, ferroportin) through viral vector delivery represents a longer-term strategy. Animal models show promise for restoring iron homeostasis [PMID: 26503257](https://pubmed.ncbi.nlm.nih.gov/PMID: 26503257).

Combination Therapies: Metal modulation combined with other approaches (anti-amyloid, anti-inflammatory) may show synergy. Trials combining chelation with standard AD treatments are under consideration.

Natural Compounds: Flavonoids and polyphenols with metal-chelating properties (curcumin, resveratrol) are being investigated as adjunct therapies. Their pleiotropic effects may address multiple pathways simultaneously.

Metal-Protein Interactions

Amyloid Beta and Metals

Aβ has high affinity for metal ions:

α-Synuclein and Metals

α-Synuclein metal interactions:

Tau and Metals

Tau-metal interactions:

Metal Binding Sites on Key Proteins

| Protein | Metal Binding Site | Affinity | Functional Impact |
|---------|-------------------|----------|-------------------|
| Aβ (1-40) | His6, His13, His14 | Cu²⁺ > Zn²⁺ > Fe³⁺ | ROS generation |
| Aβ (1-42) | His6, His13, His14, Asp1 | Higher than Aβ40 | Enhanced aggregation |
| α-Syn | N-terminal repeats | Fe³⁺ > Cu²⁺ > Zn²⁺ | Aggregation promotion |
| Tau | Multiple His residues | Fe³⁺, Zn²⁺ | Phosphorylation changes |
| SOD1 | Cu/Zn binding sites | Cu²⁺, Zn²⁺ | Enzyme dysfunction in ALS |

Biomarkers of Metal Dysregulation

Blood Biomarkers

| Biomarker | Disease | Change | Utility |
|-----------|---------|--------|---------|
| Ferritin | All | Elevated | Marker of iron stores |
| Ceruloplasmin | AD, PD | Reduced | Copper metabolism |
| Hepcidin | AD, PD | Dysregulated | Iron regulation |
| transferrin | AD | Altered | Iron transport |
| Non-transferrin-bound iron | PD | Elevated | Toxic iron species |

CSF Biomarkers

| Biomarker | Disease | Change | Reference |
|-----------|---------|--------|-----------|
| CSF iron | AD, PD | Elevated | [23](https://pubmed.ncbi.nlm.nih.gov/PMID: 26554860) |
| CSF copper | AD | Elevated | [24](https://pubmed.ncbi.nlm.nih.gov/PMID: 25848812) |
| CSF ferritin | PD | Elevated | [25](https://pubmed.ncbi.nlm.nih.gov/PMID: 28798132) |
| Ceruloplasmin | PD | Reduced | [26](https://pubmed.ncbi.nlm.nih.gov/PMID: 29438695) |

Imaging Biomarkers

Biomarkers of Metal Dysregulation

Serum/CSF Biomarkers

| Marker | Disease | Direction | Utility |
|--------|---------|-----------|---------|
| Ferritin | AD, PD, ALS, HD | ↑ | Disease progression |
| Ceruloplasmin | AD, PD | ↓ | Disease severity |
| Hepcidin | AD, PD | ↑ | Iron dysregulation |
| Transferrin | ALS | Variable | Prognosis |
| Cu/Zn SOD | ALS | Variable | Disease marker |

Imaging Biomarkers

| Technique | Metal | Utility |
|-----------|-------|---------|
| MRI (R2*) | Iron | Regional accumulation |
| QSM | Iron | Quantitative mapping |
| PET (Cu-64) | Copper | Distribution |

Cross-Disease Patterns

Disease-Specific Signatures

• AD: Metal-Aβ complexes as toxic species
• PD: Neuromelanin-iron interaction unique
• ALS: SOD1-metal relationship central
• FTD: Genetic subtype determines pattern
• HD: mHtt-metal interaction characteristic
• CBS: 4R-tau and iron dysregulation feed-forward loop
• PSP: Severe iron accumulation, oligodendrocyte vulnerability
• MSA: Oligodendroglial α-synuclein and iron interaction
• DLB: Combined AD/PD metal dysregulation patterns

Mermaid Diagram: Metal Dysregulation Pathways

References

See Also

Related Hypotheses:

• [Synthetic Biology BBB Endothelial Cell Reprogramming](/hypotheses/h-84808267)
• [Magnetosonic-Triggered Transferrin Receptor Clustering](/hypotheses/h-aa2d317c)

• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008)
• [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-01-gap-001)
• [sda-2026-04-01-gap-011](/analysis/sda-2026-04-01-gap-011)

• [ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-er-golgi-secretory-pathway-parkinsons)
• [Cytochrome Therapeutics](/experiment/exp-wiki-experiments-lipid-droplet-lysosome-axis-parkinsons)
• [FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation](/experiment/exp-wiki-experiments-ftld-tau-tdp-biomarker-differentiation)